Navigation Links
Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
Date:9/14/2009

SEATTLE, Sept. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

"PIPs were introduced by the European Commission to help ensure that medicines that may have benefit in pediatric indications are evaluated in children," said Jack Singer, CTI's Chief Medical Officer. "Anthracyclines are a mainstay in the treatment of childhood leukemias, lymphomas and solid tumors but long-term cardiotoxicity represents a significant issue. We are planning to evaluate safety and efficacy of pixantrone in pediatric cancer patients."

CTI recently received a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 in the U.S. regarding CTI's New Drug Application (NDA) for pixantrone as potential treatment for relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease return
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
3. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
4. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
5. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
6. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
7. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
8. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
9. Cell Therapeutics, Inc. Announces Exercise of Overallotment
10. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
11. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... RARITAN, N.J. , June 1, ... announced data from the Phase 3 multicenter study ... survival (PFS) with trabectedin (YONDELIS ® ) compared ... or leiomyosarcoma (LMS) previously treated with an anthracycline ... is the largest randomized Phase 3 study ever ...
(Date:6/1/2015)... 2015 About Bio-alcohols Bio-alcohols ... or cellulose. Bio-alcohols are primarily used in the transportation ... replacement for gasoline in cars. Technavio,s analysts forecast the ... 9 percent over the period 2014-2019. ... be segmented into five: transportation, infrastructure, medical, and others. ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
(Date:6/1/2015)... 2015  The Val Skinner Foundation is partnering with ... for high school students focused on cancer genetics. Skinner ... LIFE Event (LPGA Pros in the Fight to Eradicate ... West Caldwell, N.J. ... more than $500,000 on Monday, bringing the foundation,s 16-year ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Val Skinner Foundation Announces Partnership With Discovery Education 2
... the job market is showing a pulse again, Midwest technology ... employee is going to surprise them with a resignation letter ... two-week notice period? , ,Nice as it is to see ... manager whos on the hook to deliver a new product, ...
... five more Wisconsin companies qualify for tax credits under ... assistance to start-up companies, Governor Jim Doyle said on Friday. ... investors to claim tax credits after financing technology firms from ... , ,Most companies on the list are in the life ...
... students will get a one-of-a-kind experience today when they ... Space Station Expedition 10 crew. , ,The event will ... at Crossroads Elementary School, St. Paul, Minn. The event ... and Flight Engineer Salizhan Sharipov. Nearly 700 students in ...
Cached Biology Technology:Keep your tech employees happy 2Keep your tech employees happy 3Keep your tech employees happy 4
(Date:6/1/2015)... -- According to a new market ... (Government, Military & Defense, Healthcare, Banking & Finance, ... (Face Recognition, Fingerprint Recognition, Iris Recognition, Palm Recognition, ... Function (Contact and Non-Contact) & Geography ( ... , APAC, Row) - Global Forecast to 2020", ...
(Date:5/26/2015)... , May 26, 2015 ... announced the addition of the "Saudi Arabia ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Arabia is projected to grow at ... high growth is attributed to the surging demand ...
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
Breaking Biology News(10 mins):Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4
... - The American Society for Neural Therapy and ... May 1st, 2010 in Clearwater Beach, Florida, has awarded ... to Shinn-Zong Lin, MD, PhD, professor of neurosurgery at ... Hospital, Taichung, Taiwan. The award was presented in recognition ...
... transgenic mouse to display the earliest signs of Parkinson,s disease ... forms of the disease. The mouse model, which expresses ... early signs of constipation and other gastrointestinal problems that are ... As a result, researchers say, these animals could serve as ...
... In 1985 there was little hope for people with ... of emaciated figures dying from a disease that had no ... Institutes of Health,s National Cancer Institute announced it had come ... drugs discovered by this group followed. A quarter-century later in ...
Cached Biology News:ASNTR meeting presents Sanberg Awards to Prof. Lin & Prof. Dunnett 2UCSF transgenic mouse mimics Parkinson's earliest symptoms 2UCSF transgenic mouse mimics Parkinson's earliest symptoms 3Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years 2Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years 3
... agarose-digesting enzyme isolated from Pseudomonas atlantica. ... in agarose producing carbohydrate molecules that ... carbohydrate molecules will not interfere with ... Gelzyme enzyme can be used for ...
... contains the cellular components necessary for protein ... and termination factors) but has not been ... used primarily for the isolation of these ... endogenous globin mRNA. Untreated Lysate is prepared ...
...
...
Biology Products: